Experimental, research-only compounds with thin human data.
Tetrahydropyridinylpyrrolopyridine 5-HT2A partial agonists;
9-ME-BC, 9-methyl-beta-carboline, 9-methylbeta-carboline
Pozanicline; ABT-089; CAS 161417-03-4 (free base)
Navitoclax; RG 7423; RG 7433; CAS 923564-51-6
Goralatide; Seraspenide; Thymosin Beta-4 Fragment (1-4); TB4
ACD-856, NeuroRestore ACD856, ACD856 (AlzeCure)
ANAVEX 3-71; ANAVEX®3-71
Mannan polysaccharides; high-molecular-weight mannan; fungal
Arimidex, aromatase inhibitor, AI
AF710B; ANAVEX 3-71
Androsta-4,16-dien-3-one; 16-androstene class steroid; CAS 4
SRK-015; apitegromab (WHO INN)
4C-D; 4C-DOM; BL-3912A; 2-amino-1-(2,5-dimethoxy-4-methylphe
ART27.13; Artelo-27.13; AstraZeneca-derived cannabinoid agon
ASP4345; CAS 1632257-75-0
O-304; OS-01; CAS 1261289-04-6
RG1662, RO5186582, NTX-1511
BYM338; LY3985863; anti-ACVR2B antibody
Zatolmilast, BPN-14770, BPN 14770
Ladasten, bromantane analogue, Adamax
CB-03-01; Cortexolone 17α-propionate; Breezula (investigatio
Clomid, clomiphene citrate, SERM
3'-Deoxyadenosine; 3-Deoxyadenosine; NUC-7738 (ProTide deriv
Ampakine CX717; RespireRx CX717
7,8-dihydroxyflavone diethyl acetal, DHF analog
DLX159; Delix Therapeutics pipeline candidate (third-in-clas
EB-003 (Enveric Biosciences development code); "neurostabilo
LY3841136
Mexidol, emoxypine succinic acid, 2-ethyl-6-methyl-3-hydroxy
GYM-329; RG6237; RG-70240
Enclomiphene citrate, (+)-enclomiphene
RS-5441
Fluminafinil, fladrafinil hydrochloride, bis-dipropylaminoph
Fluorafinil, flmodafinil, 2-(dipropylaminophenethyl) disulfi
FST-315, FS-315, human follistatin serum isoform, follistati
REGN2477; garetosmab (INN)
Ranquilon; N-(6-phenylhexanoyl)glycyl-L-tryptophan amide
Bis-(N-monosuccinyl-L-seryl-L-methionine) hexamethylenediami
GT-20029; AR-PROTAC; androgen receptor PROTAC (topical)
S14G-Humanin, Gly14-Humanin, (Gly14)-Humanin, HNG peptide
IBIO-600; anti-myostatin/GDF-11 monoclonal antibody (AstralB
7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-
IPAM; Indole-3-propionamide; IPA (ambiguous - also used for
myo-inositol trispyrophosphate, OXY111A, inositol trispyroph
J147, curcumin/CNB-001-derived CMC compound, CAS 1146963-51-
(+)-JRT; isotryptamine-LSD; Tuck compound (informal)
JW0061; first-in-class GFRA1 agonist (JW Pharmaceutical inte
ActRII-Fc fusion; Keros Therapeutics development code KER-06
KP1, KL1-derived peptide, Klotho-derived peptide 56-87, Klot
Sipagladenant; KW-6356
A3051; KY-19382; CAS 2226664-93-1
AT-1001; CedLara (Phase 3 trial designation)
MT-2, MT-II
methylthioninium chloride, basic blue 9, CI 52015
Mvix; SK-3530; SK3530
CR-2249, CR 2249, XY-2401, nebostinel (former name); chemica
NSI-189 phosphate, benzylpiperazine derivative
NYX-2925; (2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-di
MK-0941, GIP agonist
TAK-861
ZP8396
beta-phenyl-GABA, phenylhydroxybutyric acid, baclofen analog
PP-405, PP 405 (developed by Pelage Pharmaceuticals; derived
α,N-Dipropylphenethylamine; DPPEA; MK-306; α-desmethyl-α,N-d
3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydro
Psilera-002; proprietary internal designation (no public dev
KX-826; KX-826 tincture 1.0%
Evista, raloxifene HCl, SERM
Luvesilocin; 4-OH-DiPT prodrug; 5-((3-(2-(diisopropylamino)e
FG-4592, ASP1517, AZD9941, Evrenzo (brand, EU/Japan), Aizemi
RU-58841, Fluasterone, Andriol
MIN-202, MIN202, JNJ-42847922, JNJ42847922, JNJ-922, JNJ922
Small Humanin-Like Peptide 2; SHLP-2; MT-RNR2-derived peptid
Visomitin, plastoquinonyl decyltriphenylphosphonium, PDTP, S
SLU PP 332, SLUPP332, pan-ERR agonist (research tool compoun
SRK-439; Scholar Rock anti-myostatin antibody
TBG, DLX-007, DLX007, 8-methoxy-3-methyl-2,4,5,6-tetrahydro-
Osavampator, NBI-1065845, TAK-653, CAS 1358751-06-0
BHV-2000; BMS-986089; RG6206; RO7239361
Nolvadex, tamoxifen citrate, SERM, antiestrogen
PF-06649751; CVL-751
NS2330, triple monoamine reuptake inhibitor
Coaxil, Stablon, selective serotonin reuptake enhancer, SSRE
Fareston, toremifene citrate, SERM
NA-831; cyclic glycine-proline (cGP); cycloprolylglycine (CP
REGN1033; SAR391786
Navoban; ICS 205-930; SDZ-ICS-930; ICS-205-930
Uro-B, UroB, Uro B, 3-hydroxy-6H-dibenzo[b,d]pyran-6-one, 3-
SUVN-D4010
Visudyne; benzoporphyrin derivative monoacid ring A (BPD-MA)
KED; Lys-Glu-Asp; Khavinson vascular bioregulator
KE dipeptide; Lysylglutamate; Lys-Glu; L-lysyl-L-glutamic ac
AQW-051; CAS 669770-29-0; development code AQW051
GX-50, lemairamin, cinnamoyl homoveratrylamine, CAS 29946-61
DLX-001; AAZ-A-154
CT1812; CT-1812
No compounds match that risk filter.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.